open access

Ahead of print
Original paper
Submitted: 2021-06-24
Accepted: 2021-09-20
Published online: 2021-11-04
Get Citation

The Impact of Dicer, Drosha and Exportin-5 levels in Polycystic Ovary Syndrome (PCOS) Diagnosis and Phenotyping

Gülhan Duman1, Baris Sariakcali, Serpil Ersan, Sevtap Bakir
DOI: 10.5603/EP.a2021.0096
Affiliations
  1. Turkey, sivas cumhuriyet university, 58140 sivas, Turkey

open access

Ahead of print
Original Paper
Submitted: 2021-06-24
Accepted: 2021-09-20
Published online: 2021-11-04

Abstract

Introduction: Polycystic ovary syndrome (PCOS) is a very common heterogeneous endocrine and gynecological disease in reproductive women. Early identification and treatment of patients are necessary to prevent future cardiometabolic and reproductive complications. In our study, we aimed to investigate whether Drosha, Exportin-5, and Dicer, which are involved in miRNA formation, are useful markers in the diagnosis of the disease. Material and Methods: We included patients who presented to our clinic with complaints such as menstrual irregularity, hirsutism, and acne were diagnosed with polycystic ovary after excluding other possible diagnoses, and if they meet two-thirds of the Rotterdam diagnostic criteria 30 patients with polycystic ovaries and 35 healthy controls were included in this study. Results: The mean value of Exportin5, Drosha, and Dicer markers were significantly higher in the PCOS group when compared with the control group. With the Exportin5 value >1.70, we found the PCOS with 94% probability, 86.7% sensitivity, and 91.4% specificity. Moreover, if the Drosha value is> 0.166, it is expected that the patient will be diagnosed as PCOS with a probability of 75%, 66.7% sensitivity and 71.4% specificity. A statistically significant cut-off value could not be obtained for Dicer. Conclusions: In our study, the levels of all three markers were found to be significantly higher in the PCOS group compared to the control group. It promises that they can be used in the early diagnosis of PCOS patients without full-blown. However, this preliminary study should be supported by larger-scale studies.

Abstract

Introduction: Polycystic ovary syndrome (PCOS) is a very common heterogeneous endocrine and gynecological disease in reproductive women. Early identification and treatment of patients are necessary to prevent future cardiometabolic and reproductive complications. In our study, we aimed to investigate whether Drosha, Exportin-5, and Dicer, which are involved in miRNA formation, are useful markers in the diagnosis of the disease. Material and Methods: We included patients who presented to our clinic with complaints such as menstrual irregularity, hirsutism, and acne were diagnosed with polycystic ovary after excluding other possible diagnoses, and if they meet two-thirds of the Rotterdam diagnostic criteria 30 patients with polycystic ovaries and 35 healthy controls were included in this study. Results: The mean value of Exportin5, Drosha, and Dicer markers were significantly higher in the PCOS group when compared with the control group. With the Exportin5 value >1.70, we found the PCOS with 94% probability, 86.7% sensitivity, and 91.4% specificity. Moreover, if the Drosha value is> 0.166, it is expected that the patient will be diagnosed as PCOS with a probability of 75%, 66.7% sensitivity and 71.4% specificity. A statistically significant cut-off value could not be obtained for Dicer. Conclusions: In our study, the levels of all three markers were found to be significantly higher in the PCOS group compared to the control group. It promises that they can be used in the early diagnosis of PCOS patients without full-blown. However, this preliminary study should be supported by larger-scale studies.

Get Citation

Keywords

Polycystic Ovary Syndrome (PCOS), miRNA, Dicer, Exportin-5, Drosha

About this article
Title

The Impact of Dicer, Drosha and Exportin-5 levels in Polycystic Ovary Syndrome (PCOS) Diagnosis and Phenotyping

Journal

Endokrynologia Polska

Issue

Ahead of print

Article type

Original paper

Published online

2021-11-04

DOI

10.5603/EP.a2021.0096

Keywords

Polycystic Ovary Syndrome (PCOS)
miRNA
Dicer
Exportin-5
Drosha

Authors

Gülhan Duman
Baris Sariakcali
Serpil Ersan
Sevtap Bakir

References (27)
  1. Andrade VH, Mata AM, Borges RS, et al. Current aspects of polycystic ovary syndrome: A literature review. Rev Assoc Med Bras (1992). 2016; 62(9): 867–871.
  2. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6): 981–1030.
  3. Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015; 87: 3–14.
  4. Li SC, Chan WC, Hu LY, et al. Identification of homologous microRNAs in 56 animal genomes. Genomics. 2010; 96(1): 1–9.
  5. Lee EJ, Baek M, Gusev Y, et al. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA. 2008; 14(1): 35–42.
  6. Anfossi S, Fu X, Nagvekar R, et al. MicroRNAs, Regulatory Messengers Inside and Outside Cancer Cells. Adv Exp Med Biol. 2018; 1056: 87–108.
  7. Luense LJ, Carletti MZ, Christenson LK. Role of Dicer in female fertility. Trends Endocrinol Metab. 2009; 20(6): 265–272.
  8. Ha TY. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw. 2011; 11(3): 135–154.
  9. Sørensen AE, Wissing ML, Salö S, et al. MicroRNAs Related to Polycystic Ovary Syndrome (PCOS). Genes (Basel). 2014; 5(3): 684–708.
  10. Sirotkin AV, Ovcharenko D, Grossmann R, et al. Identification of microRNAs controlling human ovarian cell steroidogenesis via a genome-scale screen. J Cell Physiol. 2009; 219(2): 415–420.
  11. Sirotkin AV, Laukova M, Ovcharenko D, et al. Identification of microRNAs controlling human ovarian cell proliferation and apoptosis. J Cell Physiol. 2010; 223(1): 49–56.
  12. Hossain MdM, Cao M, Wang Qi, et al. Altered expression of miRNAs in a dihydrotestosterone-induced rat PCOS model. J Ovarian Res. 2013; 6(1): 36.
  13. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR. ed. Polycystic ovary syndrome. Blackwell Scientific Publications, Boston 1992: 377–384.
  14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
  15. Kiconco S, Teede HJ, Azziz R, et al. International PCOS Network, International PCOS Network, International PCOS Network, International PCOS Network, International PCOS Network, International PCOS Network, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018; 89(3): 251–268.
  16. Bennasser Y, Chable-Bessia C, Triboulet R, et al. Competition for XPO5 binding between Dicer mRNA, pre-miRNA and viral RNA regulates human Dicer levels. Nat Struct Mol Biol. 2011; 18(3): 323–327.
  17. Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet. 2003; 35(3): 215–217.
  18. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. New Engl J Med. 2010; 363(19): 1877–1877.
  19. Faggad A, Budczies J, Tchernitsa O, et al. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol. 2010; 220(3): 382–391.
  20. Shao R, Norström A, Weijdegård B, et al. Distinct expression pattern of Dicer1 correlates with ovarian-derived steroid hormone receptor expression in human Fallopian tubes during ovulation and the midsecretory phase. J Clin Endocrinol Metab. 2011; 96(5): E869–E877.
  21. Lee EJ, Baek M, Gusev Y, et al. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA. 2007; 14(1): 35–42.
  22. Qin L, Chen J, Tang Li, et al. Significant Role of Dicer and miR-223 in Adipose Tissue of Polycystic Ovary Syndrome Patients. Biomed Res Int. 2019; 2019: 9193236.
  23. Roth LW, McCallie B, Alvero R, et al. Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome. J Assist Reprod Genet. 2014; 31(3): 355–362.
  24. Sang Q, Yao Z, Wang H, et al. Identification of microRNAs in human follicular fluid: characterization of microRNAs that govern steroidogenesis in vitro and are associated with polycystic ovary syndrome in vivo. J Clin Endocrinol Metab. 2013; 98(7): 3068–3079.
  25. Murri M, Insenser M, Fernández-Durán E, et al. Effects of polycystic ovary syndrome (PCOS), sex hormones, and obesity on circulating miRNA-21, miRNA-27b, miRNA-103, and miRNA-155 expression. J Clin Endocrinol Metab. 2013; 98(11): E1835–E1844.
  26. Fujimoto Y, Nakagawa Y, Shingyouchi A, et al. Dicer has a crucial role in the early stage of adipocyte differentiation, but not in lipid synthesis, in 3T3-L1 cells. Biochem Biophys Res Commun. 2012; 420(4): 931–936.
  27. Mudhasani R, Puri V, Hoover K, et al. Dicer is required for the formation of white but not brown adipose tissue. J Cell Physiol. 2011; 226(5): 1399–1406.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl